Violation of the Hormonal Spectrum in Polycystic Ovaries in Combination with Insulin Resistance. What is the Trigger: Insulin Resistance or Polycystic Ovary Disease?

Main Article Content

Lomteva S V
https://orcid.org/0000-0002-8791-1936
Shkurat T P
https://orcid.org/0000-0001-6197-7374
Bugrimova E S
https://orcid.org/0000-0003-0282-0670
Zolotykh O S
https://orcid.org/0000-0002-0090-454X
Alexandrova A A
https://orcid.org/0000-0002-1948-4995
Karantysh G V

Abstract

Polycystic ovary syndrome (PCOS) is the main cause of female infertility. The role of insulin resistance in the development of polycystic ovary is actively discussed here. The study included patients with PCOS without insulin resistance (n = 48) and with insulin resistance (n = 39). The comparison groups were patients with no history of PCOS: a control group without insulin resistance (n = 46) and a group of patients with insulin resistance (n = 45). The following parameters were determined in patients: FSH, LH, TSH, T3f, T4f, PRL, E2, 17-OHd, Pr, AMH, Test total, Testf, DHEAS, DHEASs, SHBG, ACTH, cortisol, IRI, IGF-1, C-peptide, and glucose level. The HOMA-IR index and the LH / FSH ratio and the total / SHBG test were calculated. Correlation analysis was also performed between HOMA IR and indicators of the hormonal profile, IGF-1, and C-peptide.Unidirectional changes in the levels of the following hormones were found in insulin resistance, PCOS and / or insulin resistance relative to control values: estradiol, total testosterone, cortisol, prolactin, AMG, and SHBG. As a result of the correlation analysis, negative relationships were established between the HOMA IR Index and the levels of E2, cortisol and AMH in patients (except for the control group).We assume that the formation of the phenotype of polycystic ovary with a combination of insulin resistance can be formed in patients with insulin resistance as a result of a decrease in the level of estradiol, SHBG and an increase in the content of total testosterone and AMH.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
V LS, P ST, S BE, S ZO, A AA, V KG. Violation of the Hormonal Spectrum in Polycystic Ovaries in Combination with Insulin Resistance. What is the Trigger: Insulin Resistance or Polycystic Ovary Disease?. Baghdad Sci.J [Internet]. 2022 Oct. 1 [cited 2022 Nov. 29];19(5):0990. Available from: https://bsj.uobaghdad.edu.iq/index.php/BSJ/article/view/6317
Section
article

References

Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Endocr Rev. 2015; 36(5): 487–525. DOI: 10.1210/er.2015-1018.

Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016; 106(1): 6–15. DOI: 10.1016/j.fertnstert.2016.05.003.

Saadia Z. Follicle Stimulating Hormone (LH: FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese vs. Non-Obese Women. Med Arch. 2020 Aug; 74(4): 289-293. DOI: 10.5455/medarh.2020.74.289-293.

Barrea L, Arnone A, Annunziata G, Muscogiuri G, Laudisio D, Salzano C, et al. Adherence to the Mediterranean Diet, Dietary Patterns and Body Composition in Women with Polycystic Ovary Syndrome (PCOS). Nutrients. 2019 Sep 23; 11(10): 2278. doi: 10.3390/nu11102278.

Morales-Ledesma L, Díaz Ramos JA, Trujillo Hernández A. Polycystic ovary syndrome induced by exposure to testosterone propionate and effects of sympathectomy on the persistence of the syndrome. Reprod Biol Endocrinol. 2017 Jul 10; 15(1):50. DOI: 10.1186/s12958-017-0267-0.

Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016; 37(5): 467–520. DOI: 10.1210/er.2015-1104.

Zainulabdeen J. A. Is serum amylase normal in women with polycystic ovarian syndrome? Baghdad Sci J. 2014; 11(4).

Venegas B, Gordillo LY, Rosas G, Espinoza JA, Morán C, Domínguez R, et al. In rats with estradiol valerate-induced polycystic ovary syndrome, the acute blockade of ovarian beta-adrenoreceptors improve ovulation. Reprod Biol Endocrinol. 2019 Nov 19; 17(1): 95. DOI: 10.1186/s12958-019-0539-y.

Nath CK, Barman B, Das A, Rajkhowa P, Baruah P, Baruah M, et al. Prolactin and thyroid stimulating hormone affecting the pattern of LH/FSH secretion in patients with polycystic ovary syndrome: A hospital-based study from North East India. J Family Med Prim Care. 2019 Jan; 8(1): 256-260. DOI: 10.4103/jfmpc.jfmpc_281_18.

Moghetti P, Tosi F, Castello R, Magnani CM, Negri C, Brun E, et al. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: Evidence that androgens impair insulin action in women. J. Clin. Endocrinol. Metab. 1996; 81: 952–960. doi: 10.1210/jcem.81.3.8772557.

Ibáñez L, Oberfield S E, Witchel S, Auchus R J, Chang R J, Codner E, et al. An international consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Horm Res Paediatr, 2017; 88: 371-395.

Spritzer PM, Motta AB. Adolescence and polycystic ovary syndrome: current concepts on diagnosis and treatment. Int J Clin Pract. 2015 Nov; 69(11): 1236-46. doi: 10.1111/ijcp.12719. Epub 2015 Aug 19. PMID: 26289303.

Calcaterra V, Verduci E, Cena H, Magenes V C, Todisco C F, Tenuta E, et al. Polycystic Ovary Syndrome in Insulin-Resistant Adolescents with Obesity: The Role of Nutrition Therapy and Food Supplements as a Strategy to Protect Fertility. Nutrients, 2021; 13(6): 1848.

Shaaban Z, Khoradmehr A, Amiri-Yekta A, Jafarzadeh Shirazi MR, Tamadon A. Pathophysiologic mechanisms of obesity- and chronic inflammation-related genes in etiology of polycystic ovary syndrome. Iran J Basic Med Sci. 2019 Dec; 22(12): 1378-1386. doi: 10.22038/IJBMS.2019.14029.

Escobar-Morreale HF, Santacruz E, Luque-Ramírez M, Botella Carretero JI. Prevalence of 'obesity-associated gonadal dysfunction' in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis. Hum Reprod Update. 2017 Jul 1; 23(4): 390-408. DOI: 10.1093/humupd/dmx012.

Kulshreshtha B, Pahuja I, Kothari D, Chawla I, Sharma N, Gupta S, et al. Menstrual cycle abnormalities in patients with prolactinoma and drug-induced hyperprolactinemia. Indian J Endocrinol Metab. 2017; 21: 545–50. DOI: 10.4103/ijem.IJEM_515_16

Malini NA, George KR. Evaluation of different ranges of LH: FSH ratios in polycystic ovarian syndrome (PCOS)-Clinical based case control study. Gen Comp Endocrinol. 2018; 260: 51–7. DOI: 10.1016/j.ygcen.2017.12.007.

Muderris II, Boztosun A, Oner G, Bayram F. Effect of thyroid hormone replacement therapy on ovarian volume and androgen hormones in patients with untreated primary hypothyroidism. Ann Saudi Med. 2011; 31: 145–51. DOI: 10.4103/0256-4947.77500.

Ibraheem Q A, Al Obaidy L H A, Nasir G A, Al-Obaidi M T M. 2020. Fat Mass and Obesity Association Gene Polymorphism in PCOS Iraqi Women. Baghdad Sci J, 2020; 17 (3), 1103-1103.

Al-Eisa E, Gabr SA, Alghadir AH. Effects of supervised aerobic training on the levels of anti-Mullerian hormone and adiposity measures in women with normo-ovulatory and polycystic ovary syndrome. J Pak Med Assoc. 2017 Apr; 67(4): 499-507.

The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) Hum Reprod. 2004 Jan; 19(1): 41–47.

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Hum Reprod. 2004 Jan; 19(1): 41-7. DOI: 10.1093/humrep/deh098.

Khashchenko E, Uvarova E, Vysokikh M, Ivanets T, Krechetova L, Tarasova N, et al. The Relevant Hormonal Levels and Diagnostic Features of Polycystic Ovary Syndrome in Adolescents. J Clin Med. 2020 Jun 11; 9(6): 1831. DOI: 10.3390/jcm9061831.

Gadalla MA, Norman RJ, Tay CT, Hiam DS, Melder A, Pundir J, et al. Medical and Surgical Treatment of Reproductive Outcomes in Polycystic Ovary Syndrome: An Overview of Systematic Reviews. Int J Fertil Steril. 2020 Jan; 13(4): 257-270. DOI: 10.22074/ijfs.2020.5608.

De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol. 2016; 14: 38. DOI: 10.1186/s12958-016-0173-x.

Escobar-Morreale H F, Luque-Ramírez M, San Millán J L. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev. 2005; 26(2): 251–282. doi: 10.1210/er.2004-0004.

Xita N, Lazaros L, Georgiou I, Tsatsoulis A. CYP19 gene: a genetic modifier of polycystic ovary syndrome phenotype. Fertil Steril. 2010; 94(1): 250–254. doi: 10.1016/j.fertnstert.2009.01.147.

Takayama K, Fukaya T, Sasano H, Funayama Y, Suzuki T, Takaya R, et al. Endocrinology: Iminunohistochemical study of steroidogenesis and cell proliferation in polycystic ovarian syndrome. Hum Reprod. 1996; 11(7): 1387–1392. doi: 10.1093/oxfordjournals.humrep.a019405.

Dawood A, Alkafrawy N, Saleh S, Noreldin R, Zewain S. The relationship between IL-18 and atherosclerotic cardiovascular risk in Egyptian lean women with polycystic ovary syndrome. Gynecol. Endocrinol. 2018; 34(4): 294–297. doi: 10.1080/09513590.2017.1395835.

Zhang R, Liu H, Bai H, Zhang Y, Liu Q, Guan L et al. Oxidative stress status in Chinese women with different clinical phenotypes of polycystic ovary syndrome. Clinical Endocrinology. 2017; 86(1): 88–96. doi: 10.1111/cen.13171.

Conway G, Dewailly D, Diamanti-Kandrakis E, Escobar-Morreale HF, Frank S, Gambineri A, et al. The polycystic ovary syndrome: A position statement from the European society of endocrinology. Eur J Endocrinol. 2014; 171: 1–29.

Jun TJ, Jelani AM, Omar J, Rahim RA, Yaacob NM. Serum Anti-Mullerian Hormone in Polycystic Ovary Syndrome and its Relationship with Insulin Resistance, Lipid Profile and Adiponectin. Indian J Endocrinol Metab. 2020 Mar-Apr; 24(2): 191-195. doi: 10.4103/ijem.IJEM_305_19.

Grynnerup AG, Lindhard A, Sørensen S. The role of anti-Müllerian hormone in female fertility and infertility–An overview. Acta Obstet. Gynecol. Scand. 2012; 91: 1252–60.

Diamanti-Kandarakis E. Polycystic ovarian syndrome: Pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med. 2008; 10: e3.

Park HT, Cho GJ, Ahn KH, Shin JH, Kim YT, Hur JY, et al. Association of insulin resistance with anti-mullerian hormone levels in women without polycystic ovary syndrome (PCOS) Clin Endocrinol. 2010; 72: 26–31.

Bleil ME, Gregorich SE, McConnell D, Rosen MP, Cedars MI. Does accelerated reproductive aging underlie pre-menopausal risk for cardiovascular disease? Menopause. 2013; 20: 1139.

Chen MJ, Yang WS, Chen CL, Wu MY, Yang YS, Ho HN. The relationship between anti-müllerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Hum Reprod. 2008; 23: 952–7.

Skałba P, Cygal A, Madej P, Dąbkowska-Huć A, Sikora J, Martirosian G, et al. Is the plasma anti-müllerian hormone (AMH) level associated with body weight and metabolic, and hormonal disturbances in women with and without polycystic ovary syndrome? Eur J Obstet Gynecol Reprod Biol. 2011; 158: 254–9.

Deswal R, Yadav A, Dang AS. Sex hormone binding globulin - an important biomarker for predicting PCOS risk: A systematic review and meta-analysis. Syst Biol Reprod Med. 2018 Feb; 64(1): 12-24. doi: 10.1080/19396368.2017.1410591. Epub 2017 Dec 11.

Qu X, Donnelly R. Sex Hormone-Binding Globulin (SHBG) as an Early Biomarker and Therapeutic Target in Polycystic Ovary Syndrome. Int J Mol Sci. 2020 Nov 1; 21(21): 8191. doi: 10.3390/ijms21218191.